Guidance to 2018 good practice:: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma

J. Bousquet; A Bedbrook; W Czarlewski; G. L. Onorato; S Arnavielhe; D Laune; E Mathieu-Dupas; J. Fonseca; E Costa; O Lourenço; Hilary Pinnock; Dermot Ryan; Aziz Sheikh; The MASK study group

doi:10.1186/s13601-019-0252-0

Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma

J. Bousquet, A Bedbrook, W Czarlewski, G. L. Onorato, S Arnavielhe, D Laune, E Mathieu-Dupas, J. Fonseca, E Costa, O Lourenço, Hilary Pinnock, Dermot Ryan, Aziz Sheikh, The MASK study group

Research output: Contribution to journal › Article › peer-review

Abstract

Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.

Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.

Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors.

Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.

Original language	English
Journal	Clinical and translational allergy
Volume	9
Issue number	16
DOIs	https://doi.org/10.1186/s13601-019-0252-0
Publication status	Published - 11 Mar 2019

Access to Document

10.1186/s13601-019-0252-0

Guidance to 2018 good practice...
This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdoma in/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Final published version, 2 MBLicence: Creative Commons: Attribution (CC-BY)

Fingerprint Dive into the research topics of 'Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma'. Together they form a unique fingerprint.

Cite this

Bousquet, J., Bedbrook, A., Czarlewski, W., Onorato, G. L., Arnavielhe, S., Laune, D., Mathieu-Dupas, E., Fonseca, J., Costa, E., Lourenço, O., Pinnock, H., Ryan, D., Sheikh, A., & The MASK study group (2019). Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma. Clinical and translational allergy, 9(16). https://doi.org/10.1186/s13601-019-0252-0

Bousquet, J. ; Bedbrook, A ; Czarlewski, W ; Onorato, G. L. ; Arnavielhe, S ; Laune, D ; Mathieu-Dupas, E ; Fonseca, J. ; Costa, E ; Lourenço, O ; Pinnock, Hilary ; Ryan, Dermot ; Sheikh, Aziz ; The MASK study group. / Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma. In: Clinical and translational allergy. 2019 ; Vol. 9, No. 16.

@article{1b2a1549c170461bb4b62e7ff78361e8,

title = "Guidance to 2018 good practice:: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma",

abstract = "Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient{\textquoteright}s associations, private and public sectors.Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.",

author = "J. Bousquet and A Bedbrook and W Czarlewski and Onorato, {G. L.} and S Arnavielhe and D Laune and E Mathieu-Dupas and J. Fonseca and E Costa and O Louren{\c c}o and Hilary Pinnock and Dermot Ryan and Aziz Sheikh and {The MASK study group}",

year = "2019",

month = mar,

day = "11",

doi = "10.1186/s13601-019-0252-0",

language = "English",

volume = "9",

journal = "Clinical and translational allergy",

issn = "2045-7022",

publisher = "BioMed Central",

number = "16",

}

Bousquet, J, Bedbrook, A, Czarlewski, W, Onorato, GL, Arnavielhe, S, Laune, D, Mathieu-Dupas, E, Fonseca, J, Costa, E, Lourenço, O, Pinnock, H , Ryan, D , Sheikh, A & The MASK study group 2019, 'Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma', Clinical and translational allergy, vol. 9, no. 16. https://doi.org/10.1186/s13601-019-0252-0

Guidance to 2018 good practice: ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma. / Bousquet, J.; Bedbrook, A; Czarlewski, W; Onorato, G. L.; Arnavielhe, S; Laune, D; Mathieu-Dupas, E; Fonseca, J.; Costa, E; Lourenço, O; Pinnock, Hilary ; Ryan, Dermot ; Sheikh, Aziz; The MASK study group.

In: Clinical and translational allergy, Vol. 9, No. 16, 11.03.2019.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Guidance to 2018 good practice:

T2 - ARIA digitally‑enabled, integrated, person‑centred care for rhinitis and asthma

AU - Bousquet, J.

AU - Bedbrook, A

AU - Czarlewski, W

AU - Onorato, G. L.

AU - Arnavielhe, S

AU - Laune, D

AU - Mathieu-Dupas, E

AU - Fonseca, J.

AU - Costa, E

AU - Lourenço, O

AU - Pinnock, Hilary

AU - Ryan, Dermot

AU - Sheikh, Aziz

AU - The MASK study group

PY - 2019/3/11

Y1 - 2019/3/11

N2 - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors.Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.

AB - Aims: Mobile Airways Sentinel NetworK (MASK) belongs to the Fondation Partenariale MACVIA-LR of Montpellier, France and aims to provide an active and healthy life to rhinitis sufferers and to those with asthma multimorbidity across the life cycle, whatever their gender or socio-economic status, in order to reduce health and social inequities incurred by the disease and to improve the digital transformation of health and care. The ultimate goal is to change the management strategy in chronic diseases.Methods: MASK implements ICT technologies for individualized and predictive medicine to develop novel care pathways by a multi-disciplinary group centred around the patients.Stakeholders: Include patients, health care professionals (pharmacists and physicians), authorities, patient’s associations, private and public sectors.Results: MASK is deployed in 23 countries and 17 languages. 26,000 users have registered.

U2 - 10.1186/s13601-019-0252-0

DO - 10.1186/s13601-019-0252-0

M3 - Article

VL - 9

JO - Clinical and translational allergy

JF - Clinical and translational allergy

SN - 2045-7022

IS - 16

ER -